

Colorectal Cancer™

U P D A T E

Conversations with Clinical Investigators
Bridging the Gap between Research and Patient Care

EDITOR

Neil Love, MD

FACULTY

Steven D Wexner, MD

Neal J Meropol, MD

Mark S Roh, MD

Paulo M Hoff, MD



Colorectal Cancer Update for Surgeons

A Continuing Medical Education Audio Series

STATEMENT OF NEED/TARGET AUDIENCE

Colorectal cancer is one of the most rapidly evolving fields in oncology. Published results from a plethora of ongoing clinical trials lead to the continuous emergence of new therapeutic techniques, agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing colorectal cancer surgeon must be well informed of these advances. To bridge the gap between research and patient care, *Colorectal Cancer Update for Surgeons* utilizes one-on-one discussions with leading colorectal cancer investigators. By providing access to the latest research developments and expert perspectives, this CME program assists colorectal surgeons in the formulation of up-to-date clinical management strategies.

GLOBAL LEARNING OBJECTIVES

- Critically evaluate the clinical implications of emerging clinical trial data in colorectal cancer treatment in order to incorporate these data into local and systemic management strategies in the neoadjuvant, adjuvant and metastatic disease settings.
- Counsel appropriately selected patients about the availability of ongoing clinical trials.
- Evaluate the emerging research data on various adjuvant chemotherapy approaches, including the use of oxaliplatin-containing regimens and the use of capecitabine or intravenous 5-FU.
- Evaluate emerging research data on various neoadjuvant radiation therapy/chemotherapy approaches for rectal cancer and explain the absolute risks and benefits of these regimens to patients.
- Describe and implement an algorithm for medical and radiation oncology referral for appropriately selected patients with colorectal cancer for consideration of systemic therapy.
- Describe the risks and benefits of various surgical approaches to isolated metastases of colorectal cancer.
- Assess the number of resected lymph nodes required to adequately determine the risk of recurrence in patients with colon cancer.

PURPOSE OF THIS ISSUE OF *COLORECTAL CANCER UPDATE FOR SURGEONS*

The purpose of Issue 2 of *Colorectal Cancer Update for Surgeons* is to support these global objectives by offering the perspectives of Drs Wexner, Meropol, Roh and Hoff on the integration of emerging clinical research data into the management of colorectal cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 2.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs, review the CME information and complete the Post-test and Evaluation Form located in the back of this book or on our website, ColorectalCancerUpdate.com/Surgeons.

FACULTY AFFILIATIONS

Steven D Wexner, MD

Chief, Division of Colorectal Surgery
Cleveland Clinic Florida
Weston, Florida

Neal J Meropol, MD

Director, Gastrointestinal Cancer Program
Director, Gastrointestinal Tumor Risk
Assessment Program
Divisions of Medical Science
and Population Science
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Mark S Roh, MD

Chair, Department of Surgery, Allegheny
General Hospital
Director, Division of Surgical Oncology
Professor, Human Oncology
Drexel University College of Medicine
Pittsburgh, Pennsylvania

Paulo M Hoff, MD

Executive Director
Hospital Sirio Libanes
São Paulo, Brazil

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lillian Sklaver Poltorack, PharmD, Ginelle Suarez, Chris Thomson, MD, MS, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech Inc/OSI Pharmaceuticals Inc, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Wexner — Consulting Fees: Baxter International Inc, Boston Scientific Corporation, Curon Medical Inc, Incontinence Devices Inc, Power Medical Interventions Inc; Grants/Research Support: Curon Medical Inc, Ethicon Inc, Ethicon Endo-Surgery Inc, Incontinence Devices Inc, Karl Storz Endoscopy-America Inc, Medtronic Inc, National Institutes of Health, SurgRx Inc; Stock Options: Intuitive Surgical Inc, MedSurge Medical Inc, Power Medical Interventions Inc; Scientific Advisory Board Member: CB Fleet Company Inc. **Dr Meropol** — Consulting Fees: Amgen Inc, Genentech Inc, Pfizer Inc. **Dr Roh** — No financial interests or affiliations to disclose. **Dr Hoff** — Contracted Research: Amgen Inc, Genentech Inc, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

If you would like to discontinue your complimentary subscription to *Colorectal Cancer Update for Surgeons*, please email us at Info@ResearchToPractice.net, or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

QUESTIONS (PLEASE CIRCLE ANSWER):

1. The Clinical Outcomes of Surgical Therapy (COST) study compared open colectomy to laparoscopic colectomy for colon cancer.
 - a. True
 - b. False
2. Tumor markers are routinely used in clinical practice for predicting response and assignment of patients to bevacizumab therapy.
 - a. True
 - b. False
3. Which of the following regimens has been shown to be superior to 5-FU/leucovorin in patients with Stage III colon cancer?
 - a. IFL (irinotecan/5-FU/leucovorin)
 - b. FOLFOX (oxaliplatin/5-FU/leucovorin)
 - c. Both a and b
 - d. None of the above
4. In patients with Stage II colon cancer, which of the following characteristics would suggest an increased risk of recurrence?
 - a. Obstruction
 - b. Perforation
 - c. Lymphovascular invasion
 - d. All of the above
 - e. None of the above
5. Which of the following side effects are associated with FOLFOX?
 - a. Neutropenia
 - b. Neurotoxicity
 - c. Diarrhea
 - d. All of the above
 - e. None of the above
6. Which of the following is an orally administered chemotherapy agent?
 - a. Oxaliplatin
 - b. Capecitabine
 - c. Irinotecan
 - d. Both a and b
 - e. None of the above
7. The side effects associated with capecitabine include diarrhea and hand-foot syndrome.
 - a. True
 - b. False
8. NSABP-C-09 is evaluating the addition of intrahepatic FUDR to CAPOX for patients with surgically resected or ablated hepatic metastases from colon cancer.
 - a. True
 - b. False
9. The MOSAIC trial and NSABP-C-07 both evaluated a 5-FU/leucovorin regimen in combination with _____ as adjuvant therapy for patients with colon cancer.
 - a. Irinotecan
 - b. Capecitabine
 - c. Oxaliplatin
 - d. All of the above
 - e. None of the above
10. The QUASAR trial demonstrated close to a five percent benefit in _____ for adjuvant chemotherapy in patients with Stage II colon cancer.
 - a. Disease-free survival
 - b. Progression-free survival
 - c. Overall survival
 - d. All of the above
 - e. None of the above

EVALUATION FORM

Colorectal Cancer Update for Surgeons — Issue 2, 2006

Research To Practice respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please complete this evaluation form. A certificate of completion will be issued upon receipt of your completed evaluation form.

Please answer the following questions by circling the appropriate rating:

5 = Outstanding 4 = Good 3 = Satisfactory 2 = Fair 1 = Poor N/A = Not applicable to this issue of *CCU* for Surgeons

GLOBAL LEARNING OBJECTIVES

To what extent does this issue of *CCU* for Surgeons address the following global learning objectives?

- Critically evaluate the clinical implications of emerging clinical trial data in colorectal cancer treatment in order to incorporate these data into local and systemic management strategies in the neoadjuvant, adjuvant and metastatic disease settings. 5 4 3 2 1 N/A
- Counsel appropriately selected patients about the availability of ongoing clinical trials. 5 4 3 2 1 N/A
- Evaluate the emerging research data on various adjuvant chemotherapy approaches, including the use of oxaliplatin-containing regimens and the use of capecitabine or intravenous 5-FU. 5 4 3 2 1 N/A
- Evaluate emerging research data on various neoadjuvant radiation therapy/chemotherapy approaches for rectal cancer and explain the absolute risks and benefits of these regimens to patients. 5 4 3 2 1 N/A
- Describe and implement an algorithm for medical and radiation oncology referral for appropriately selected patients with colorectal cancer for consideration of systemic therapy. 5 4 3 2 1 N/A
- Describe the risks and benefits of various surgical approaches to isolated metastases of colorectal cancer. 5 4 3 2 1 N/A
- Assess the number of resected lymph nodes required to adequately determine the risk of recurrence in patients with colon cancer. 5 4 3 2 1 N/A

EFFECTIVENESS OF THE INDIVIDUAL FACULTY MEMBERS

Faculty	Knowledge of subject matter	Effectiveness as an educator
Steven D Wexner, MD	5 4 3 2 1	5 4 3 2 1
Neal J Meropol, MD	5 4 3 2 1	5 4 3 2 1
Mark S Roh, MD	5 4 3 2 1	5 4 3 2 1
Paulo M Hoff, MD	5 4 3 2 1	5 4 3 2 1

OVERALL EFFECTIVENESS OF THE ACTIVITY

- Objectives were related to overall purpose/goal(s) of activity. 5 4 3 2 1 N/A
- Related to my practice needs. 5 4 3 2 1 N/A
- Will influence how I practice. 5 4 3 2 1 N/A
- Will help me improve patient care. 5 4 3 2 1 N/A
- Stimulated my intellectual curiosity. 5 4 3 2 1 N/A
- Overall quality of material. 5 4 3 2 1 N/A
- Overall, the activity met my expectations. 5 4 3 2 1 N/A
- Avoided commercial bias or influence. 5 4 3 2 1 N/A

Which of the following audio formats of this program did you use?

- Audio CDs Downloaded MP3s from website

EVALUATION FORM

Colorectal Cancer Update for Surgeons — Issue 2, 2006

REQUEST FOR CREDIT — please print clearly

Name: Specialty:

Degree:

MD DO PharmD NP BS RN PA Other

Medical License/ME Number: Last 4 Digits of SSN (required):

Street Address: Box/Suite:

City, State, Zip:

Telephone: Fax:

Email:

Research To Practice designates this educational activity for a maximum of 2.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be _____ hour(s).

Signature: Date:

Will the information presented cause you to make any changes in your practice?

Yes No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity:

.....

What other topics would you like to see addressed in future educational programs?

.....

What other faculty would you like to hear interviewed in future educational programs?

.....

Additional comments about this activity:

.....

FOLLOW-UP

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:

Yes, I am willing to participate in a follow-up survey. No, I am not willing to participate in a follow-up survey.

CCUS206 To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Evaluation Form and mail or fax both to: Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131, FAX 305-377-9998. You may also complete the Post-test and Evaluation online at ColorectalCancerUpdate.com/Surgeons.

Colorectal Cancer™

U P D A T E

Editor/CME Director	Neil Love, MD
Managing Editor	Kathryn Ault Ziel, PhD
Scientific Director	Richard Kaderman, PhD
Writers	Lillian Sklaver Poltorack, PharmD Douglas Paley
Continuing Education Administrator for Nursing	Sally Bogert, RNC, WHCNP
Content Validation	Margaret Peng Ginelle Suarez Erin Wall
Director, Creative and Copy Editing	Aura Herrmann
Creative Manager	Fernando Rendina
Graphic Designers	Jason Cunnius Tamara Dabney Shantia Daniel Elisa Stambouli
Senior Production Editor	Alexis Oneca
Managing Production Coordinator	Tere Sosa
Copy Editors	Dave Amber Mary DiNunzio Rosemary Hulce Kirsten Miller Pat Morrissey/Havlin Carol Peschke Susan Petrone
Production Manager	Patricia Kappes
Audio Production	Frank Cesarano
Technical Services	Arly Ledezma
Web Master	John Ribeiro
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: NLove@ResearchToPractice.net
For CME Information	Email: CME@ResearchToPractice.net

Copyright © 2006 Research To Practice. All rights reserved.

This program is supported by education grants from Roche Laboratories Inc and Sanofi-Aventis.

The compact discs, internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Colorectal Cancer™

U P D A T E

Copyright © 2006 Research To Practice.
This program is supported by education grants from
Roche Laboratories Inc and Sanofi-Aventis.



Sponsored by Research To Practice.

Last review date: November 2006
Release date: November 2006
Expiration date: November 2007
Estimated time to complete: 2.5 hours